Zentalis Pharmaceuticals, Inc. Common Stock (ZNTL)

PHARMACEUTICAL PREPARATIONS

Zentalis Pharmaceuticals, Inc. Common Stock (ZNTL) is listed on Nasdaq, where it has traded since April 3, 2020.

Listed On
Nasdaq
Listed Since
April 3, 2020
Employees
106
Market Cap
$256M

About Zentalis Pharmaceuticals, Inc. Common Stock

Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.

Institutional ownership

In 13F filings for the quarter ended June 30, 2026, 111 institutions reported holding ZNTL, with 47.4 million shares worth $228.9 million in aggregate. The largest reported holder was Vanguard, with 4.0 million shares worth $19.4 million. Of the 5 largest holders listed below, 4 added shares and 1 held its position unchanged during the quarter.

InstitutionSharesValueQuarter change
Vanguard4,002,882$19MAdded 33.54%
5am Venture Management3,947,913$19MUnchanged
BlackRock3,753,525$18MAdded 195.59%
Squadron Capital Management3,700,000$18MAdded 1.9%
Two Sigma Investments3,024,936$15MAdded 2.31%

Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.

Frequently asked questions

What is ZNTL?

Zentalis Pharmaceuticals, Inc. Common Stock (ZNTL) is listed on Nasdaq, where it has traded since April 3, 2020.

Who are the largest institutional holders of ZNTL?

In 13F filings for the quarter ended June 30, 2026, the largest reported holders of ZNTL were Vanguard, 5am Venture Management and BlackRock.

How many institutions own ZNTL?

111 institutions reported a position in ZNTL for the quarter ended June 30, 2026, worth $228.9 million in total.

Did institutions buy or sell ZNTL last quarter?

Of the 5 largest reported holders, 4 added shares and 1 held its position unchanged during the quarter. Every reported holder and its change is on the SentiSense ownership page for ZNTL.

Every reported institutional holder, plus insider and congressional trades in ZNTL, on SentiSense.